Rosacea Clinical Trial - Rifaximin Treatment of Papulopustular Rosacea

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

Clinical Trial Description

100 patients will be randomized into two groups.

Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days, and after a 4-week washout period, receive one placebo tablet three times a day for 14 days.

Group B will receive placebo first, and then rifaximin with the same dosage schedule to Group A.

Assessments will be performed before application and 4 weeks after the last dosage, for both of rifaximin and placebo. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Rosacea

Clinical Trial Details

NCT number	NCT01359228
Study type	Interventional
Source	University of California, San Francisco
Contact
Status	Withdrawn
Phase	Phase 2
Start date	April 2013
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05597462` - Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks	Phase 1
Completed	`NCT02601963` - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea	Phase 2
Completed	`NCT02249065` - Mirvaso in Use Study	Phase 4
Completed	`NCT02292797` - Assessment of the Rosacea Prevalence in the General Population	N/A
Completed	`NCT01659853` - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea	Phase 3
Completed	`NCT01426269` - Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo	Phase 4
Completed	`NCT00991198` - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage	Phase 2
Terminated	`NCT04336163` - Skin Imaging to Inform Laser Treatments	N/A
Recruiting	`NCT04108897` - Analysis of the Microbiome in Rosacea	Early Phase 1
Completed	`NCT03872050` - Deep Phenotyping of Rosacea and Migraine
Active, not recruiting	`NCT06033352` - Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea	Phase 2
Completed	`NCT03263273` - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea	Phase 2
Completed	`NCT04508205` - CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes	Phase 1
Completed	`NCT04508660` - CGB-400 for the Reduction of Facial Redness	Phase 1
Completed	`NCT05094700` - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants	N/A
Active, not recruiting	`NCT03211585` - EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA	N/A
Completed	`NCT02637232` - Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Completed	`NCT02576847` - Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel	Phase 3
Completed	`NCT02576860` - Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle	Phase 3
Completed	`NCT02583009` - A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea	Phase 2